Clinical trials: Migraine Without Aura
Chronic Migraine, Chronic Migraine, Headache
A Study to Evaluate the Efficacy and Safety of TNX-1900 in Patients With Chronic Migraine
This is a phase 2, double-blind, randomized, multicenter, placebo-controlled, three arm parallel study to evaluate the efficacy and safety of two different dosages (30 IU daily and 60 IU daily) of TNX-1900 in patients with…
- Conditions
- Chronic Migraine, Chronic Migraine, Headache, Chronic Migraine Without Aura, Aura Migraine
- Trial name
- PREVENTION (NCT05679908)
- Testing
- TNX-1900
- Where
- 26 sites in United States
- Volunteers
- 88 people
- Sponsor
- Tonix Pharmaceuticals, Inc.
Migraine, Common Migraine
A Study of the Efficacy and Safety of Topiramate in the Prevention of Migraine
The purpose of this study is to evaluate the safety and efficacy of three doses of topiramate (50 milligrams[mg], 100mg, and 200mg per day) compared with placebo in the prevention of migraine.
- Conditions
- Migraine, Common Migraine, Classic Migraine, Headache
- Trial name
- NCT00231595
- Testing
- topiramate
- Volunteers
- 768 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Acute Treatment of Migraine
Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine
The purpose of this study is to test the long-term safety of rimegepant in the acute treatment of migraine in children and adolescents (≥ 6 to < 18 years of age).
- Trial name
- NCT04743141
- Testing
- Rimegepant (PF-07899801)
- Where
- 124 sites in United States, Poland and 1 more
- Volunteers
- 600 people
- Sponsor
- Pfizer
Migraine With or Without Aura
Three Doses of Lasmiditan (50 mg, 100 mg and 200 mg) Compared to Placebo in the Acute Treatment of Migraine
This is a prospective randomized, double-blind, placebo-controlled study in participants with disabling migraine (Migraine Disability Assessment (MIDAS) score ≥ 11).
- Trial name
- SPARTAN (NCT02605174)
- Testing
- Lasmiditan 50 mg, Lasmiditan 100 mg, Lasmiditan 200 mg
- Where
- 95 sites in United States
- Volunteers
- 3,005 people
- Sponsor
- Eli Lilly and Company
Migraine, With or Without Aura
Safety and Efficacy in Adult Subjects With Acute Migraines
The purpose of this study is to compare the efficacy of BHV-3000 (rimegepant) versus placebo in subjects with Acute Migraines
- Trial name
- NCT03237845
- Testing
- Rimegepant
- Where
- 50 sites in United States
- Volunteers
- 1,499 people
- Sponsor
- Pfizer
Migraine With or Without Aura
Comparative Study of Oral Eletriptan (40mg and 80mg), Oral Sumatriptan (25mg and 50mg) and Placebo
The objective of this study was to compare the efficacy, toleration and safety of eletriptan 40mg and 80mg, with sumatriptan 25mg and 50mg, and placebo when given orally to subjects with an acute migraine.
- Trial name
- NCT01986270
- Testing
- Eletriptan 40 mg, Eletriptan 80 mg, Sumatriptan 25 mg
- Volunteers
- 1,141 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Pediatric Migraine
Randomized Study in Children and Adolescents With Migraine: Acute Treatment
The purpose of this study is to test the safety and efficacy of BHV-3000 versus placebo in the acute treatment of moderate or severe migraine in children and adolescents.
- Trial name
- NCT04649242
- Testing
- Rimegepant/BHV3000
- Where
- 246 sites in United States, Canada and 7 more
- Volunteers
- 2,100 people
- Sponsor
- Pfizer
Migraine, Pain
A Study to Assess the Efficacy and Safety of Oral CL-H1T in the Treatment of Acute Migraine Pain
A Study to Assess the Efficacy and Safety of Oral CL-H1T in the Treatment of Acute Migraine Pain.
- Conditions
- Migraine, Pain, Nausea, Vomiting
- Trial name
- NCT03877718
- Testing
- Arm 1: CL-H1T, Arm 2: CL-H1T, Arm 3: Sumatriptan Succinate 100 mg capsule
- Where
- 3 sites in United States
- Volunteers
- 475 people
- Sponsor
- Charleston Laboratories, Inc
Migraine With and Without Aura
Low-Dose Naltrexone and Acetaminophen Combination and Sumatriptan in the Acute Treatment of Migraine With Nausea
This proof-of-concept study compares side-by-side low-dose naltrexone and acetaminophen combination to sumatriptan in the acute treatment of migraine.
- Trial name
- NCT03185143
- Testing
- Naltrexone and Acetaminophen Combination, Sumatriptan 100 mg
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Allodynic Therapeutics, Inc
Migraine
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)
Migraine is a common neurological disorder typically characterized by attacks of throbbing, moderate to severe headache, often associated with nausea, vomiting, and sensitivity to light and sound.
- Trial name
- Ubro Peds (NCT05125302)
- Testing
- Ubrogepant
- Where
- 129 sites in United States, Puerto Rico
- Volunteers
- 1,059 people
- Sponsor
- AbbVie
Headache Disorders, Primary, Migraine With Aura
IndoProCaf Effervescent Tablets Effectiveness in Acute Treatment of Migraine and/or Episodic Tension-type Headache and Patients' Satisfaction With the Treatment in Routine Clinical Practice
Headaches are a common medical problem that physicians frequently encounter in their practice. One of key findings of The Atlas of Headache Disorders prepared by World Health Organization (WHO) is: headache disorders, including…
- Conditions
- Headache Disorders, Primary, Migraine With Aura, Migraine Without Aura, Tension-Type Headache
- Trial name
- PRESTO (NCT02115269)
- Where
- 30 sites in Kazakhstan, Ukraine
- Volunteers
- 759 people
- Sponsor
- Abbott
Migraine With or Without Aura
Eletriptan for the Treatment of Migraine in Patients With Previous Poor Response or Tolerance to Oral Sumatriptan
To determine the tolerability and efficacy of eletriptan in patients who had discontinued oral sumatriptan due to lack of efficacy or intolerable adverse events (AEs) during previous clinical treatment (not a controlled trial).
- Trial name
- NCT01989936
- Testing
- Eletriptan 40 mg, Eletriptan 80 mg
- Where
- 43 sites in Denmark, Finland and 3 more
- Volunteers
- 446 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Migraine, Without Aura
TREXIMET (Formerly Known as TREXIMA) for the Acute Treatment of Probable Migraine (ICHD-II 1.6.1)
This study was designed to determine the efficacy and tolerability of TREXIMET (formerly known as TREXIMA) compared to placebo for the acute treatment of probable migraine, a sub-type of migraine.
- Trial name
- NCT00387881
- Testing
- sumatriptan succinate / naproxen sodium
- Where
- 70 sites in United States
- Volunteers
- 679 people
- Sponsor
- GlaxoSmithKline
Migraine Disorders
A Study to Determine the Effect of Sumatriptan and Naproxen Sodium Combination Tablet, Sumatriptan Tablet, and Naproxen Sodium Tablet on Blood Pressure When Treating Migraine Headaches That Occur During a 6-month Period
The purpose of this study is to test the effect on blood pressure of sumatriptan and naproxen sodium combination tablets, tablets containing only sumatriptan, and tablets containing only naproxen sodium when these drugs are taken…
- Trial name
- NCT00792636
- Testing
- sumatriptan and naproxen sodium combination tablet, sumatriptan tablet, naproxen sodium tablet
- Where
- 49 sites in United States
- Volunteers
- 407 people
- Sponsor
- GlaxoSmithKline
Migraine
Safety and Efficacy Trial of MTX101 2mg for the Acute Treatment of Migraine in Adults
The goal of this clinical trial is to learn if drug MTX101 works to treat acute migraine attacks in adults. It will also learn about the safety of the drug MTX101.
- Trial name
- NCT06728553
- Testing
- MTX101
- Where
- 7 sites in United States
- Volunteers
- 78 people
- Sponsor
- Manistee Therapeutics
Episodic Migraine
DFN-11 Injection in Episodic Migraine With or Without Aura
Safety and Efficacy of DFN-11 in patients with episodic migraines with or without aura.
- Trial name
- RESTOR (NCT02569853)
- Testing
- DFN-11
- Where
- 16 sites in United States
- Volunteers
- 268 people
- Sponsor
- Dr. Reddy's Laboratories Limited
Acute Migraine With or Without Aura in Adolescents
A Study to Evaluate the Safety and Tolerability of Rizatriptan for Long Term Treatment of Acute Migraine in Children and Adolescents (MK-0462-086 AM3)
To provide long term safety data for rizatriptan in children and adolescents. The primary hypothesis of the study is that rizatriptan is well tolerated in the long term treatment of acute migraine in pediatric patients age 12-17…
- Trial name
- NCT01004263
- Testing
- rizatriptan benzoate
- Volunteers
- 674 people
- Sponsor
- Organon and Co
Migraine, Migraine With Aura
A Study of the PK and Safety of Single Doses of STS101, DHE Injection and Nasal Spray in Healthy Subjects
Single-center, single-dose, open-label, 5-period crossover (in each part), pharmacokinetic and safety study.
- Conditions
- Migraine, Migraine With Aura, Migraine Without Aura
- Trial name
- NCT05337254
- Testing
- Dihydroergotamine
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Satsuma Pharmaceuticals, Inc.
Migraine With or Without Aura
Efficacy, Safety, and Tolerability of Oral Eletriptan for Treatment of Acute Migraine
To confirm the efficacy of three dose levels of oral eletriptan relative to placebo in relieving symptoms of acute migraine and to further explore the dose response relationship of eletriptan.
- Trial name
- NCT01978496
- Testing
- Eletriptan 20 mg, Eletriptan 40 mg, Eletriptan 80 mg
- Volunteers
- 1,334 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Migraine Without Aura, Migraine With Aura
Dose Ranging Study of the Efficacy and Tolerability of Tonabersat in the Prophylaxis of Migraine Headache
Primary objective: To investigate the efficacy and tolerability of two doses of tonabersat compared to placebo in the prophylaxis of migraine headache and to evaluate the longer term tolerability of tonabersat in an open label…
- Trial name
- TEMPUS (NCT00534560)
- Testing
- Tonabersat
- Volunteers
- 542 people
- Sponsor
- Minster Research Ltd